Cogent Biosciences (NASDAQ:COGT) Shares Down 4.5% – Time to Sell?

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) traded down 4.5% during trading on Wednesday. The company traded as low as $30.98 and last traded at $30.2250. 208,606 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 2,157,045 shares. The stock had previously closed at $31.64.

More Cogent Biosciences News

Investors following COGT have been watching these news items:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $56 price target while raising its FY2027 EPS estimate to a loss of $1.09 from $1.28. It also turned its Q3 2027 forecast from a loss of $0.26 to earnings of $0.19 per share, and narrowed its projected Q4 2027 loss. HC Wainwright Forecasts Strong Price Appreciation for Cogent Biosciences
• Neutral Sentiment: A report noted conflicting analyst views on Cogent, underscoring that expectations are not uniformly positive. Analysts Have Conflicting Sentiments on Cogent Biosciences
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 and Q1 2027 EPS forecasts slightly. Separately, Cogent reported a quarterly loss of $0.59 per share, missing the consensus estimate of a $0.56 loss.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on COGT shares. Guggenheim lifted their target price on shares of Cogent Biosciences from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Friday, October 2nd. Wedbush reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Cogent Biosciences in a research note on Wednesday, September 16th. Wall Street Zen cut Cogent Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th. Finally, Piper Sandler increased their price objective on Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.57.

Cogent Biosciences Stock Down 0.9%

The stock’s 50 day simple moving average is $31.52 and its two-hundred day simple moving average is $35.36. The firm has a market cap of $5.07 billion, a P/E ratio of -12.95 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a current ratio of 10.99 and a quick ratio of 13.57.

Cogent Biosciences (NASDAQ:COGT) last issued its quarterly earnings results on Thursday, November 5th. The technology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). As a group, research analysts forecast that Cogent Biosciences, Inc. will post -2.28 earnings per share for the current year.

Institutional Investors Weigh In On Cogent Biosciences

Several hedge funds have recently added to or reduced their stakes in COGT. First Trust Advisors LP purchased a new position in shares of Cogent Biosciences in the third quarter worth $254,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Cogent Biosciences during the third quarter valued at $225,000. Voya Investment Management LLC boosted its position in shares of Cogent Biosciences by 6.4% during the third quarter. Voya Investment Management LLC now owns 1,013,501 shares of the technology company’s stock valued at $32,452,000 after buying an additional 60,744 shares during the last quarter. Virtus Advisers LLC boosted its position in shares of Cogent Biosciences by 25.1% during the third quarter. Virtus Advisers LLC now owns 14,419 shares of the technology company’s stock valued at $462,000 after buying an additional 2,895 shares during the last quarter. Finally, Aberdeen Group plc boosted its position in shares of Cogent Biosciences by 49.7% during the third quarter. Aberdeen Group plc now owns 588,628 shares of the technology company’s stock valued at $18,848,000 after buying an additional 195,394 shares during the last quarter.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.